Medicare might restrict patient access to Alzheimer’s treatment priced at $56,000 for a year’s supply to soften the financial blow to the federal insurance program’s budget.
“Whether or not that drug will be covered by Medicare and Medicaid is is an outstanding question, something that HHS will have to deal with,” said Health and Human Services Secretary Xavier Becerra last week.
Real journalism.Trusted by millions.
Unlimited access to in-depth reporting, expert analysis, and the stories that shape our country.
Subscribe Now
Already a member? Log in
Print subscriber? Click here to login/register your account
Digital subscriber? Click here to login/register your account.